Categories: News

Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

A recording of the presentation will be available beginning on Monday, November 22, 2021, at 10:00 a.m. Eastern Time. Interested parties may access the presentation in the Events section of Vapotherm’s Investor website at: http://investors.vapotherm.com/.

About Vapotherm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.2 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.

Contacts

Investor Relations Contacts:
Mark Klausner or Mike Vallie, Westwicke, an ICR Company, ir@vtherm.com, +1 (603) 658-0011

Staff

Recent Posts

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…

2 hours ago

IntelePeer Agentic AI Trend Report Cites Trust, Day-One Value, Integration, and Analytics as Critical Success Factors in Healthcare Deployments

2026 Outlook: automated Agentic AI workflows will rapidly emerge as business imperatives to meet patient…

2 hours ago

Netsmart Strengthens Interoperability Leadership Through CMS Health Technology Ecosystem Pledge

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#CMSAlignedNetwork--Netsmart, an industry-leading provider of healthcare technology solutions and services for community-based…

2 hours ago

The Naderi Center Announces the Rise of “Facial Harmony” as 2025’s Leading Trend in Aesthetic Surgery and Dermatology

From combination surgeries to advanced skin therapies, The Naderi Center outlines how patients nationwide are…

2 hours ago

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

5 hours ago